Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents

We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yoo-Yeon, Choe, Young June, Kim, Jia, Kim, Ryu Kyung, Jang, Eun Jung, Park, Seon Kyeong, Lim, Do-Sang, Yi, Seonju, Lee, Sangwon, Kwon, Geun-Yong, Shin, Jee Yeon, Choi, Sang-Yoon, Jeong, Mi Jin, Park, Young-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622254/
https://www.ncbi.nlm.nih.gov/pubmed/36191615
http://dx.doi.org/10.3201/eid2811.220918
Descripción
Sumario:We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During February 16–May 7, 2022, among 972,449 eligible persons, 736,439 (75.7%) received a first booster and 236,010 (24.3%) persons received a second booster. Compared with the first booster group, at 30–53 days, the second booster recipients had vaccine effectiveness (VE) against all infections of 22.28% (95% CI 19.35%–25.11%), VE against critical infection of 56.95% (95% CI 29.99%–73.53%), and VE against death of 62.96% (95% CI 34.18%–79.15%). Our findings provide real-world evidence that a second booster dose of mRNA vaccine substantially increases protection against critical infection and death in these high-risk population groups.

Ejemplares similares